Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects

NCT01010542 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

39

Enrollment

INDUSTRY

Sponsor class

Stopped See termination reason in detailed description.

Conditions

Plaque Psoriasis

Interventions

DRUG: ILV-095 300 mg in a 4 to 1 ratio
DRUG: ILV-095 300 mg in a 4 to 1 ratio

Sponsor

Pfizer